Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

JNJ – Potential Buy Opportunity at Support LevelThe JNJ stock price is currently approaching a key demand zone. If the price finds support and bullish confirmation signals appear, such as bullish candlestick patterns or long lower wicks, we could see a potential rebound. The first target for this move would be around the $153.03 level. This setup offers an opportunity for a long position if the demand zone holds. Traders should monitor for additional confirmation before entering. Do you agree with this analysis, or do you have alternative views on this setup? Share your thoughts in the comments!
NYSE:JNJLong
by DanieIM
Johnson & Johnson (JNJ) Posted Q4 Earnings BeatJohnson & Johnson (JNJ) recently reported its fourth-quarter earnings, showcasing a performance that beat analyst expectations with an EPS of $2.04 against a forecast of $1.99 and sales of $22.52 billion, in line with the anticipated $22.45 billion. Despite this positive financial news, J&J's stock took a tumble, closing down 1.9% at $145.27 after issuing guidance for 2025 that fell short of Wall Street's expectations. The company projected sales between $89.2 billion and $90 billion, below the Street's estimate of $91.04 billion, and an adjusted profit per share from $10.50 to $10.70, bracketing the consensus of $10.55. A Mixed Bag Innovative Medicines Shine: J&J's innovative medicines segment saw a 4.4% growth, contributing significantly to the quarter's performance. Standout performers included Spravato, which grew by 44% year-over-year, and cancer drugs like Darzalex and Erleada, alongside blood thinners which increased by nearly 30%. However, the looming patent expiration for Stelara, a major immunology drug, casts a shadow over future earnings from this segment. MedTech Segment Under Pressure: On the downside, medical device sales underperformed, coming in at $8.19 billion against expectations of $8.22 billion. This segment faces challenges, particularly in China, but there's optimism with new investments and product launches like the Ottava surgical robot, which could challenge Intuitive Surgical's market dominance in the future. External Headwinds: J&J is dealing with several external pressures including foreign exchange issues, which have impacted their sales guidance for 2025. Additionally, potential generic competition and ongoing litigation related to talc products continue to be significant headwinds. Technical Analysis Premarket Recovery: Despite the post-earnings drop, NYSE:JNJ shares showed a 0.60% uptick in premarket trading on Thursday, suggesting some investor confidence returning. RSI and Patterns: The Relative Strength Index (RSI) at 50.48 indicates a moderate condition, neither overbought nor oversold, providing a balanced outlook. The stock's monthly chart shows a falling wedge pattern, typically a bullish indicator if broken upwards. A breakout above this pattern could signal a bullish campaign for $JNJ. However, there's a risk of further decline if the support at $145 breaks, potentially leading to a dip towards the one-month low of $140. Moving Averages: NYSE:JNJ currently trades below its 50-day moving average, suggesting short-term bearish sentiment, but a recovery above this average could signal the beginning of a recovery trend. Forward-Looking Perspective Despite the immediate challenges, analysts like Edward Jones' John Boylan see J&J's guidance as conservative but achievable, particularly with the company's strategic focus on new product development and pipeline expansion in both pharmaceuticals and medical technology. The emphasis on cancer drugs, robotics, and cardiovascular products is seen as a pathway to long-term growth and margin expansion. Conclusion Johnson & Johnson, while grappling with short-term headwinds, holds a portfolio of products with strong growth potential. The technical setup suggests that if JNJ can maintain or surpass current support levels, there's room for optimism. Investors might see this as an opportunity to buy into a dip, given the company's history of innovation and resilience. However, caution is advised due to the external factors and regulatory challenges ahead. The broader narrative for J&J seems to hinge on its ability to innovate and adapt in a rapidly changing healthcare market environment.
NYSE:JNJLong
by DEXWireNews
Johnson & Johnson: Awaiting ResultsJohnson & Johnson (NYSE: JNJ), one of the global giants in the pharmaceutical, medical device and consumer sectors, is in the spotlight as it prepares to release its fourth-quarter 2024 results. Analysts and the market expect the results to reflect a combination of macroeconomic challenges and strategic opportunities that will define its performance in 2025. Expected Q4 2024 results 1. Pharmaceuticals: The pharmaceutical business remains the key revenue driver for J&J, driven by drugs such as Stelara (treatment for immune diseases) and Darzalex (multiple myeloma). However, the recent loss of exclusivity for some products could affect revenues, especially in key markets such as the United States and Europe. o Expected revenues: Moderate growth of 3-5% year-on-year is projected in the pharmaceutical segment. 2. Medical devices: The post-pandemic recovery has favored this segment, with an increase in surgical procedures and advanced therapies. However, supply chain issues and high material costs could limit gains. 3. Consumer products: The consumer division, now under the Kenvue brand, has experienced stable growth thanks to products such as Tylenol and Neutrogena. However, competition in this market remains intense, which could limit profit margins. Technical analysis with WACD The company is currently in a price correction that began in September 2024 and has moved since December last year in a range between $150 and $142 a share. Currently there have been bearish signals in the WACD indicator in its WVAP signal that show us that it can correct its price again in that range. On the other hand the smoothed triple mean seems to be extending its move from the recent lows, indicating that this signal could be short-lived and could send the price subsequently towards the high end of the range if the expected results are as indicated. Outlook for 2025 1. Pharmaceutical innovation: Johnson & Johnson has strengthened its focus on research and development, with a robust pipeline that includes oncology treatments and advanced gene therapies. Expected new drug approvals could be a key catalyst for long-term growth. 2. Legal Challenges: Litigation related to talc and other consumer products continues to be a source of uncertainty. While J&J has established a compensation fund, legal costs could affect its results in 2025. 3. Digital transformation and sustainability: The company is investing in digital technologies to improve operational efficiency and in sustainability initiatives that align its business model with market and regulatory expectations. Conclusion Johnson & Johnson faces a mixed picture in the near term, with challenges in some key segments and growth opportunities in others. Fourth quarter 2024 results will be crucial in gauging its ability to overcome current pressures and capitalize on its innovation strategy in 2025. With a focus on diversification and innovation, J&J remains a benchmark in the healthcare sector, but its success will depend on how it manages legal and macroeconomic risks in the coming years. Ion Jauregui - ActivTrades Analyst ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acing on the information provided does so at their own risk.
NYSE:JNJ
by ActivTrades
Johnson & Johnson Sees Possible Bullish Chart Ahead of EarningsJohnson & Johnson NYSE:JNJ will report Q4 numbers next Wednesday (Jan. 22) at a time when the medical company’s stock has been under the weather, falling back some 14% since early September even as the S&P 500 gained about 7%. What does JNJ’s technical and fundamental analysis say could happen from here? Let’s look: Johnson & Johnson’s Fundamental Analysis The Street is looking for JNJ to report $2.04 in adjusted Q4 earnings per share on $22.5 billion in revenue. That would reflect about 4.9% in sales growth year over year, but also show a 10.9% drop in adjusted EPS from the $2.29 that Johnson & Johnson saw in Q4 2023. Of the 15 sell-side analysts that I know of who follow JNJ, all 15 have revised their Q4 estimates lower since the quarter began. But the company also had some interesting news this week. On Monday, Johnson & Johnson announced the acquisition of biopharma firm Intra-Cellular Therapies NASDAQ:ITCI for $14.6 billion, or a cool $132 per share in an all-cash deal. The idea is to strengthen JNJ's neurosciences portfolio. At least the firm recognizes that either you grow organically or you “buy” growth. Doing nothing isn’t usually a good solution. Intra-Cellular Therapies brings with it a drug called Caplyta, an oral treatment for schizophrenia. Caplyta generated more than $175 million in sales for Q3, up from less than $126 million in the same quarter one year earlier. ITCI isn’t a cash-flow beast by any stretch, but the firm has no debt on the balance sheet. So, JNJ is buying potential, not somebody else's financial problems. In fact, Intra-Cellular had more than $1 billion in cash on hand as of Sept. 30. Additionally, ITCI has a promising candidate (ITI-128) currently in Phase 2 testing as a potential therapy for generalized anxiety disorder and Alzheimer's-related psychosis. Johnson & Johnson’s Technical Analysis Now let’s look at Johnson & Johnson’s chart going back six months: Readers will see that the stock has been very responsive since the summer to traditional technical analysis. JNJ developed a so-called “rising wedge” from July into September, as denoted by green shading at the chart’s left. That’s historically a pattern of bearish reversal. The rising wedge ultimately culminated in a “double-top” pattern of bearish reversal, which apexed in both early and mid-September (marked with two red boxes in the above chart). Lo and behold, the stock became mired in a downward trend after that. However, JNJ has recently developed a “falling wedge,” denoted by the red box at right. That’s usually a pattern of bullish reversal. Readers will also note that Johnson & Johnson’s most recent low occurred right around the time the stock suffered a "death cross.” That’s when a stock’s 50-day Simple Moving Average (Or “SMA,” marked with a blue line) crosses below its 200-day SMA (the red line). This often causes a negative algorithmic reaction that leads to further bearish behavior. I don't know when (or if) the falling-wedge pattern’s bullishness will come to fruition, but I do know that Johnson & Johnson could definitely use a positive catalyst. Next week’s Q4 earnings could provide that, as CEO Joaquin Duato will get a chance to talk up the Intra-Cellular Therapies acquisition during the company’s earnings call. I also know that JNJ is pressuring its 21-day Exponential Moving Average (or “EMA,” marked with a green line) from below. That could put swing traders on alert. Such activity could put the 50-day SMA in play if there’s a rebound. That could serve as the stock’s upside pivot point. As for other technical indicators, Johnson & Johnson’s Relative Strength Index (the gray line at the chart’s top) looks like it’s improving. However, the stock’s daily Moving Average Convergence Divergence indicator (or “MACD”) shows that both the 12-day EMA (the black line at the chart’s bottom) and the 26-day EMA (the gold line) remain mired in negative territory. Still, the histogram of JNJ’s 9-day EMA (the blue bars at bottom) has recently found its way into positive territory. (Moomoo Technologies Inc. Markets Commentator Stephen “Sarge” Guilfoyle” had no position in JNJ at the time of writing this column.) This article discusses technical analysis, other approaches, including fundamental analysis, may offer very different views. The examples provided are for illustrative purposes only and are not intended to be reflective of the results you can expect to achieve. Specific security charts used are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. This content is also not a research report and is not intended to serve as the basis for any investment decision. The information contained in this article does not purport to be a complete description of the securities, markets, or developments referred to in this material. Moomoo and its affiliates make no representation or warranty as to the article's adequacy, completeness, accuracy or timeliness for any particular purpose of the above content. Furthermore, there is no guarantee that any statements, estimates, price targets, opinions or forecasts provided herein will prove to be correct. Moomoo is a financial information and trading app offered by Moomoo Technologies Inc. In the U.S., investment products and services on Moomoo are offered by Moomoo Financial Inc., Member FINRA/SIPC. TradingView is an independent third party not affiliated with Moomoo Financial Inc., Moomoo Technologies Inc., or its affiliates. Moomoo Financial Inc. and its affiliates do not endorse, represent or warrant the completeness and accuracy of the data and information available on the TradingView platform and are not responsible for any services provided by the third-party platform.
NYSE:JNJ
by moomoo
1
Strong bullish rebound at bottom of the support level JNJ is eyeing a potential bottoming out action after price action shows strong bullish buying pressure since 10 Jan 2025. Yesterday's bullish candle was stronger than usual and it has closed above the conversion and base line of the ichimoku. Long-term MACD is still bearish but mid-term Stochastic Oscillator has shown an oversold crossover. Near-term 23-period ROC is back above the zero line. We could take a buy based on strong buying volume and is at the bottom of the consolidative range.
NYSE:JNJLong
by William-trading
The Top 2 Stocks To Short-Sell In This Bear Market ComingIn this video, you will see the top 2 stocks to short-sell in this bear market coming. Its sad to note that w are in a bear market but you can still learn more about how to spot the stocks that are trending downwards in this bear market in the stock market so to learn more watch this video right right now also you will see how to use the rocket booster strategy and candle stick patterns So remember in this video you will see: ->2 Candlestick patterns ->The rocket booster strategy ->Two top stocks that are leading the bear market in the stock market Rocket boost this content to learn more Disclaimer: Trading is risky please learn risk management and profit-taking strategies also feel free to use a simulation trading tools before you trade with real money.
NYSE:JNJShort
by lubosi
Johnson & Johnson (JNJ): 2024 Challenges, 2025 OpportunitiesJohnson & Johnson could become one of the standout plays for 2025 if key levels are respected. A Brief Recap of NYSE:JNJ in 2024 Johnson & Johnson experienced a challenging year. The company finalized the spin-off of its Consumer Health division, sharpening its focus on Pharmaceuticals and MedTech. In April, J&J completed the acquisition of Shockwave Medical for $12.5 billion, strengthening its cardiovascular MedTech portfolio. Financially, the company performed well, surpassing Q3 expectations with $22.5 billion in revenue (+5.2% YoY) and an EPS of $2.42. Despite the positives, the stock faced significant headwinds, peaking at $170 in August before dropping to $140 by December—a 15% decline over the quarter. While we briefly considered a potential outperformance in 2024, we refrained from entering a long position, which proved to be the right decision. Looking ahead, 2025 may offer renewed opportunities. For NYSE:JNJ to regain bullish momentum, it must respect the lower edge of the long-standing trend channel established in October 2021. Ideally, we would like to see a fake-out below this channel to trigger a bearish shakeout, followed by a reversal that targets higher levels. For the longer term, our outlook includes the potential to test the $116–$100 range. However, if our 2025 thesis aligns with technical developments, we will consider adding exposure to $JNJ.
NYSE:JNJLong
by freeguy_by_wmc
2
Johnson & Johnson Analysis | UpdatedIn this case of Johnson & Johnson (JNJ) stock, it is at a sensitive point where support from a descending channel on the daily chart is being challenged. This level can be a turning point for the stock and if the level holds, then there is a possibility of the stock rising to the $155 – $157 range as shown by the potential target. There are some technical indicators which show that the downtrend is weakening and there is a possibility of the prices turning around in the near future as the MACD depicts a bullish divergence while the RSI shows that the prices are in the oversold region. Also, volume will be a major tool in determining the validity of the reversal. Thus, if the stock goes up, the volume should increase substantially, which would increase the probability of the stock reaching the channel’s upper edge. From the macroeconomic perspective, the current Fed Funds interest rate and the negative Sharpe Ratio suggest that the market is becoming more cautious, which, however, does not rule out the possibility of the stock movements similar to those of JNJ. This is a make-or-break time for the asset. If support continues to hold and there are other signs of a reversal such as patterns or higher volumes then JNJ can experience a substantial change in trend.
NYSE:JNJShort
by Gui_Cabral
Johnson & Johnson | Analysis In this case of Johnson & Johnson (JNJ) stock, it is at a sensitive point where support from a descending channel on the daily chart is being challenged. This level can be a turning point for the stock and if the level holds, then there is a possibility of the stock rising to the $155 – $157 range as shown by the potential target. There are some technical indicators which show that the downtrend is weakening and there is a possibility of the prices turning around in the near future as the MACD depicts a bullish divergence while the RSI shows that the prices are in the oversold region. Also, volume will be a major tool in determining the validity of the reversal. Thus, if the stock goes up, the volume should increase substantially, which would increase the probability of the stock reaching the channel’s upper edge. From the macroeconomic perspective, the current Fed Funds interest rate and the negative Sharpe Ratio suggest that the market is becoming more cautious, which, however, does not rule out the possibility of the stock movements similar to those of JNJ. This is a make-or-break time for the asset. If support continues to hold and there are other signs of a reversal such as patterns or higher volumes then JNJ can experience a substantial change in trend.
NYSE:JNJLong
by Gui_Cabral
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market price (CMP) near a double-bottom structure, a second purchase around the $138–$136 range (61.8% Fibonacci level), and a third at the $133–$135 channel bottom. A stop loss is defined at $130 on a closing basis to manage downside risk, emphasizing disciplined trading within the defined channel boundaries.
NYSE:JNJLong
by jayshafiq2
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
JNJ Long consolidation..potential breakoutNYSE:JNJ has been consolidating for over 2 years on this range now: * monthly bull flag * forming the right shoulder of an IHS on weekly chart (can even see it on the monthly) * healthcare sector oversold, so can see a bounce a bounce could push JNJ to test the upper trendline at 165-166. The IHS neckline is at ~170 and the measured move puts it at around 185+ Play: 2026 leaps might be ideal here as they have low IV and can increase in value rapidly I am looking at the 185C for Jan 2026 Resistance: 165 (volume node + 200WMA), 170 (volume node) 172, 175, 180 Support: 150 trade becomes invalid on weekly close below 150
NYSE:JNJLong
by siddheshmuley1462
$150 support for JNJ?$150 was a popular area from April to July. Once it finally broke through, it went to its high for the year of $168. Even after a good earning report, JNJ has been on the decline since. It hopefully found support at $150. It stayed in the support range for two days and immediately had the bullish engulfing candle, a nice sign. In addition, this same period had RSI dip below 30. Only other time this happened this year was in April and that lasted for less than 10 days. JNJ appears to be getting crushed with all the other Big Pharma. Overreaction in my opinion. JNJ moved -10% in 18 days. That's a big move for a company like that. This is not a meme stock. This is, dare I say it, a blue chip stock. I am not an attorney, accountant or financial advisor, nor am I holding myself out to be, and the information contained in this post is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation
NYSE:JNJ
by DrConservative